Articles tagged with Ovarian Cancer
Researchers found that mutations in ARID1a gene sensitize certain tumors to PARP inhibitor drugs, allowing for more effective treatment options. The study highlights the importance of using genomic information to guide cancer therapy and identify precise treatments for individual patients.
Researchers discovered ovarian cancer cells can lock into survival mode and avoid chemotherapy destruction. The study, published in Nature, used whole genome sequencing to analyse tumour DNA samples from 91 patients with high-grade serous ovarian cancer.
Researchers at University of California, San Diego, have identified six mRNA isoforms that distinguish ovarian cancer cells from normal cells, offering potential for early diagnosis and targeted therapies. The study's findings may also lead to new therapeutic targets and more effective treatment options.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A Cancer Research UK study found that pre-surgery chemotherapy reduces side effects and hospital stays, leading to a better quality of life for patients. The trial challenged the international standard for treating advanced ovarian cancer.
PharmaMar presents clinical studies showcasing the efficacy of YONDELIS and PM1183 in treating small cell lung cancer, soft tissue sarcoma, and malignant pleural mesothelioma. The studies demonstrate promising results with a response rate of 67% for PM1183 in SCLC.
Myriad Genetics presented 19 clinical studies on advanced companion diagnostic and molecular diagnostic tests for cancer treatment and prevention. The company's research focuses on personalized medicine, including selecting effective pharmaceuticals, preventing disease through hereditary cancer tests, and optimizing treatment decisions...
A new screening method can detect twice as many women with ovarian cancer as conventional strategies, according to the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The method uses a statistical calculation to interpret changing CA125 levels in women's blood, providing a more accurate prediction of individual risk.
Researchers found that patients with anti-TP53 autoantibodies can detect ovarian cancer up to 13 months before rising CA125 levels. The study suggests a novel assay method for earlier detection of the disease.
Researchers from MD Anderson Cancer Center are part of two new Stand Up to Cancer Dream Teams focused on lung cancer driven by KRAS mutations and preventing high-risk ovarian cancer. The teams aim to test combination therapies and launch prevention efforts.
A new ovarian cancer research team, funded by a $6 million grant, will focus on DNA repair therapies and prevention. The team aims to build on recent clinical advances with PARP inhibitors and develop a new web-based approach to genetic testing and counseling.
Researchers successfully migrated immune cells to tumor sites in patients with mesothelin-expressing tumors. The treatment showed no major adverse events, suggesting patients tolerated it well, with T cells targeting and surviving at tumor sites for up to 28 days.
A study has identified molecular changes that occur in tissue after chemotherapy in ovarian cancer patients. The researchers found that these changes could be potential targets for new, more personalized drugs. The findings have the potential to advance treatments for ovarian cancer.
A recent study suggests that genetic testing for BRCA1 and BRCA2 mutations in women with ovarian cancer can help identify carriers and reduce their risk. The study found that 19% of women with the most common form of ovarian cancer carry these mutations, which is higher than previous estimates.
Researchers at the University of Utah Health have discovered patterns in DNA anomalies that predict a woman's outcome significantly better than tumor stage, also indicating how well she'll respond to platinum therapy. The new method could lead to personalized prognostic and diagnostic laboratory tests.
Researchers found that specific BRCA mutations are linked to higher breast cancer risk and lower ovarian cancer risk, potentially leading to more personalized risk assessment and prevention strategies. The study analyzed data from over 31,000 women with BRCA1 or BRCA2 gene mutations.
A study of over 31,000 women with BRCA1 and BRCA2 mutations found that the risk of breast and ovarian cancer varies by mutation type. The findings suggest that knowledge of mutation-specific risks could inform clinical decision-making among carriers.
A breakthrough discovery by Queen's University researcher Madhuri Koti has identified biomarkers that can predict the success of chemotherapy in ovarian cancer patients. This finding holds promise for improving treatment options and increasing patient survival rates.
A study published in Nature Structural & Molecular Biology reveals that human DNA polymerase theta may be a promising drug therapy target for inhibiting breast cancer. The researchers used X-ray crystallography to determine the first crystal structures of POLQ, providing insights into its role in DNA repair and genomic instability.
The Anderson Algorithm increases surgical success in advanced ovarian cancer by providing a personalized approach to surgery, resulting in high complete resection rates of over 86%. This milestone is strongly tied to improved survival outcomes for patients.
A Cancer Research UK study found that serous ovarian cancers with diverse genetic profiles are more likely to become resistant to chemotherapy and recur. This variability affects the prognosis of patients with these tumors, leading to earlier deaths compared to those with less varied tumors.
Researchers at The Wistar Institute have identified a new therapeutic target in ovarian clear cell carcinoma, a difficult-to-treat subtype of ovarian cancer. EZH2 inhibition causes regression of ovarian tumors with ARID1A mutation, providing a much-needed therapeutic strategy for clear cell ovarian cancer.
A meta-analysis of 52 studies found that short-term hormone replacement therapy (HRT) use is associated with a significantly increased risk of developing the two most common types of ovarian cancer. Women who used HRT for 5 years or more had a 40% higher likelihood of developing ovarian cancer compared to those who never took HRT.
Researchers at the University of Chicago Medical Center have created a new screening tool for ovarian cancer that can rapidly test compounds to block metastasis. The three-dimensional cell-culture system mimics human tissue and has identified small molecules that inhibit adhesion and invasion.
Researchers at Dartmouth have found that introducing a specific strain of bacteria into the microenvironment of ovarian cancer tumors can transform tumor cells from suppressors to attackers, sparking a strong anti-tumor immune response. The study's results demonstrate a new potential for treating various types of cancers.
Researchers discovered a new way to shrink ovarian cancer tumors by inhibiting abnormal angiogenesis. Using a naturally occurring protein inhibitor called 3TSR, the approach improved chemotherapy drug delivery and resulted in significant tumor regression and survival.
A team of UNC genetics researchers discovered how two genes interact to trigger cancer and spur its development. The research found that ARID1A and PIK3CA mutations led to the overproduction of Interleukin-6, a cytokine crucial for cell signaling that triggers inflammation.
A groundbreaking TGen-led discovery has identified the likely genetic cause of a rare form of ovarian cancer that affects young women and girls. The study found nearly universal underpinnings for this disease, which usually presents in advanced stages and is resistant to standard chemotherapy.
Researchers have found that loss of gene PTEN is a common driver event behind high-grade serous ovarian cancer, which is often fatal. Combining image analysis with genetic data helped identify PTEN levels in cancer cells while ignoring normal cells, paving the way for new treatments.
Researchers at MD Anderson Cancer Center discovered that targeting the non-coding microRNA miR569 can increase cell death in ovarian and breast cancers. The study also found that silencing miR569 expression improves survivability outcomes for ovarian patients.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Scientists have found a biological indicator that can predict which women without BRCA1/2 mutations will respond well to the PARP inhibitor rucaparib. The biomarker is related to genomic loss of heterozygosity, and its presence indicates that patients with ovarian cancers may benefit from treatment.
Researchers found that cirmtuzumab induces senescence in cancer stem cells, degrading their ability to grow and metastasize. Ovarian cancer patients with high levels of ROR1 experienced more aggressive forms of the disease, highlighting the potential of this antibody therapy as a targeted treatment.
Researchers at University of Guelph found a potential breakthrough in treating late-stage ovarian cancer by shrinking tumours and improving drug delivery. This approach may lead to novel treatment options with reduced morbidity and mortality.
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
Researchers at Lund University discovered that lactose intolerant people are at a reduced risk of developing lung, breast, and ovarian cancers. The study, which analyzed nationwide data from Sweden, suggests that diet plays a crucial role in protecting against these cancers.
Tea and citrus fruits/juices associated with reduced risk of developing ovarian cancer. Flavonols/flavanones found in foods high in these compounds significantly decrease ovarian cancer risk.
A recent study found that a higher overall diet quality was associated with a lower risk of mortality among ovarian cancer survivors. The composite effect of healthy dietary choices on survival suggests that individual components may not be as crucial as previously thought.
A study by Myriad Genetics presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting shows that its Tumor BRACAnalysis CDx test identifies cancer-causing BRCA1/2 mutations in 44% more patients than germline blood testing. This could expand treatment options for ovarian cancer patients with these genetic mutations.
A study of over 93,000 women found that increases in skirt size are strongly associated with a higher risk of postmenopausal breast cancer. Women who gained one size every 10 years were 33% more likely to develop the disease, while those who gained two sizes faced an 77% greater risk.
A recent study published in PNAS reveals the link between gelsolin protein and ovarian cancer resistance, providing a promising avenue for developing new therapies. By cutting down gelsolin levels, researchers found that chemo-resistant cells become susceptible to chemotherapy.
Research finds HE4 hormone plays key role in modulating ovarian cancer response to hormones and therapies. The study identified a mechanism by which hormonal therapies like Tamoxifen and Fulvestrant restore sensitivity to chemotherapy in HE4-overexpressing tumors.
Ovarian cancer cells use mesothelial cells to spread through the body via fibronectin secretion. The study suggests that mesothelium is an active participant in the spread of ovarian cancer.
A phase Ib clinical trial found that olaparib tablets were safe and effective in heavily pretreated ovarian cancer patients, particularly those with BRCA mutations. The treatment regimen provided a response rate of 66 percent and no grade 4 toxicities, making it a promising option for improving cure rates and quality of life.
A team led by Lin Zhang identified a non-protein-coding RNA, FAL1, whose expression is linked to ovarian cancer. The study found that blocking the activity of FAL1 reduces cancer cells' growth and may serve as a biomarker for BRCA-related cancer prognosis.
Researchers at A*STAR's Institute of Medical Biology have identified a biomarker, Lgr5, to detect ovarian cancer earlier. Bioinformatics analysis has also revealed genes whose mutation status can be used for prognosis and development of personalized treatment.
Researchers at MD Anderson Cancer Center have discovered that circulating tumor cells (CTCs) rely on the HER3 receptor protein to metastasize to the omentum, a fatty tissue covering abdominal organs. High expression of HER3 is associated with shorter survival in ovarian cancer patients.
A 30-year follow-up study found no link between fertility drugs and breast, ovarian, and uterine cancers, except for extended use of clomiphene citrate. The study of 12,193 women treated for infertility showed a higher risk of invasive breast cancer with clomiphene use in 12 or more treatment cycles.
A study published in JNCI: Journal of the National Cancer Institute found that a shorter time to first cigarette (TTFC) is associated with an increased risk of lung cancer in both heavy and light smokers. The researchers analyzed data from over 3,200 current and former smokers, revealing that TTFC was statistically significantly higher...
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
Researchers have discovered a protein called focal adhesion kinase (FAK) that plays a crucial role in ovarian cancer cell growth. A network of signals generated by osteopontin and FAK controls spheroid growth, making it a potential target for new therapies.
Researchers at the University of Adelaide have identified a genetic pathway that suppresses the spread of ovarian cancer. By studying the genetics of platypus and humans, they found that piRNA genes play a crucial role in preventing the growth of cancer cells.
The Myriad myRisk test detects significantly more deleterious mutations than single cancer tests and helps solve the overlap dilemma among hereditary cancer syndromes. The test evaluates 25 clinically significant genes associated with eight major hereditary cancers.
Researchers used gene expression arrays to analyze biopsies from ICON7 patients and found that patients with proliferative and mesenchymal subtypes responded best to bevacizumab. This subtype analysis may help identify patients who will benefit from the treatment, potentially reducing unnecessary toxicity.
A phase I and II clinical trial demonstrated a near doubling of progression-free survival benefit for the combination therapy compared to olaparib alone. The study results showed significant improvement with the use of the combination drug therapy for recurrent ovarian cancer, suggesting a new treatment option for patients.
A clinical trial has shown that a combination of drugs, including olaparib and cediranib, can significantly improve progression-free survival for patients with recurrent ovarian cancer. The study found that the combination therapy doubled the benefit of using olaparib alone.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
A new study of women with BRCA mutations who underwent risk-reducing salpingo-oophorectomy found high rates of sexual dysfunction, menopausal symptoms, and poor sleep. Hormone replacement therapy provided relief for some patients, highlighting the need for better strategies to manage long-term effects.
An analysis by Fox Chase Cancer Center has revealed a dramatic increase in the use of chemotherapy before surgery to remove ovarian cancer, with 26.72% of patients receiving it in 2011 compared to 8.94% in 1998.
A meta-analysis of 44 studies found that breastfeeding, tubal ligation, and oral contraceptives are associated with reduced rates of ovarian cancer in BRCA1 mutation carriers. Smoking may raise the risk of breast cancer for patients with a BRCA2 mutation.